LONDON — November 26, 2025. Tangram Therapeutics has submitted a Clinical Trial Application (CTA) to the UK Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 first-in-human clinical study of TGM-312, a novel GalNAc-siRNA therapeutic candidate for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). This marks a defining milestone for the company as it transitions into a clinical-stage RNAi developer, leveraging its proprietary GalOmic RNAi platform and AI-driven discovery engine. The company anticipates the trial will begin in early 2026, with initial data expected in the second half of the year.
Science Significance
The CTA submission highlights the scientific potential of TGM-312, a GalOmic GalNAc-conjugated small interfering RNA (siRNA) engineered to silence a novel hepatocyte-expressed gene implicated in MASH pathogenesis. According to the file, TGM-312 demonstrated dramatic reductions in NAFLD Activity Score, decreased hepatic inflammation, and slowed fibrosis progression in translational GAN-DIO mouse models, both as monotherapy and in combination with other MASH therapies. The therapy’s quarterly subcutaneous dosing regimen offers a patient-friendly profile, and its highly selective RNAi silencing mechanism represents a next-generation precision-medicine approach to a disease with complex metabolic and inflammatory drivers.
Regulatory Significance
The MHRA submission signals the formal entry of Tangram’s GalOmic RNAi platform into regulated clinical development—a substantial advancement for a biotechnology company founded on computational discovery. The proposed Phase 1/2 trial will assess safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory liver biomarkers, including biopsy evaluations, meeting core expectations of early-stage regulatory frameworks. As the company’s first CTA, this milestone reflects Tangram’s growing maturity in navigating GCP standards, clinical governance, and early-phase regulatory expectations, positioning TGM-312 for potential accelerated development if clinical outcomes align with the strong preclinical profile.
Business Significance
Advertisement
This CTA submission represents Tangram’s official elevation to a clinical-stage biopharmaceutical company, bringing significant credibility to its pipeline strategy and its integrated AI + RNAi discovery model. Moving TGM-312 into human testing strengthens investor confidence and enhances Tangram’s competitive positioning in the rapidly expanding metabolic-disease therapeutics market. With MASH representing a multibillion-dollar global opportunity and few effective treatments available, clinical validation of TGM-312 could catalyze strategic partnerships, broaden funding opportunities, and establish Tangram as a differentiated player in the next wave of RNAi-driven metabolic therapies.
Patients’ Significance
MASH is a high-burden chronic condition affecting millions worldwide, often progressing to cirrhosis, liver failure, or transplant if left untreated. Many patients experience poor therapeutic options or limited response to existing interventions. The emergence of TGM-312 provides hope for a targeted, infrequent dosing therapy that addresses upstream disease-driving mechanisms. The upcoming clinical study’s inclusion of exploratory biomarkers, imaging, and liver biopsies will offer deeper insight into how TGM-312 may influence metabolic and inflammatory pathways, ultimately shaping more effective treatment strategies for patients facing serious unmet needs.
Policy Significance
As healthcare systems confront rising incidence of obesity-driven liver diseases, including MASH, the introduction of new RNAi-based treatments is highly relevant to public health planning, reimbursement strategy, and future clinical guidelines. Effective therapies that reduce disease progression could significantly lessen long-term healthcare burdens, including hospitalizations and liver-transplant demand. Tangram’s advancement into clinical testing aligns with broader policy priorities to support innovative, high-impact therapeutic platforms, particularly those leveraging precision-medicine technologies like RNAi to address chronic metabolic diseases with escalating societal and economic consequences.
With the CTA submission for TGM-312, Tangram Therapeutics steps into a new phase of growth, bringing forward a promising RNAi therapeutic that combines cutting-edge gene-silencing technology, computational discovery, and scalable clinical ambition. As the Phase 1/2 program prepares to launch in early 2026, the company is positioned to generate foundational human data that may validate its GalOmic platform and signal major progress for patients with MASH. The milestone marks not only a scientific and corporate achievement but also a meaningful advancement in the pursuit of precision therapies for complex metabolic diseases.
Source: Tangram Therapeutics press release
